vs
ICU MEDICAL INC（ICUI）与森萨塔科技（ST）财务数据对比。点击上方公司名可切换其他公司
森萨塔科技的季度营收约是ICU MEDICAL INC的1.7倍（$934.8M vs $540.7M），森萨塔科技净利率更高（9.3% vs -2.9%，领先12.2%），森萨塔科技同比增速更快（2.6% vs -14.1%），森萨塔科技自由现金流更多（$104.6M vs $36.0M），过去两年ICU MEDICAL INC的营收复合增速更高（-2.3% vs -5.0%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
森萨塔科技控股有限公司是全球领先的工业科技企业，主营传感器、电气保护及控制解决方案的研发、生产与销售，产品覆盖汽车、工业、航空航天、暖通空调、电信等多个下游领域，服务全球制造类企业客户。
ICUI vs ST — 直观对比
营收规模更大
ST
是对方的1.7倍
$540.7M
营收增速更快
ST
高出16.7%
-14.1%
净利率更高
ST
高出12.2%
-2.9%
自由现金流更多
ST
多$68.6M
$36.0M
两年增速更快
ICUI
近两年复合增速
-5.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $934.8M |
| 净利润 | $-15.7M | $87.1M |
| 毛利率 | 37.5% | 30.6% |
| 营业利润率 | 1.0% | 15.1% |
| 净利率 | -2.9% | 9.3% |
| 营收同比 | -14.1% | 2.6% |
| 净利润同比 | 34.0% | 24.6% |
| 每股收益（稀释后） | $-0.63 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIST
| Q1 26 | — | $934.8M | ||
| Q4 25 | $540.7M | $917.9M | ||
| Q3 25 | $537.0M | $932.0M | ||
| Q2 25 | $548.9M | $943.4M | ||
| Q1 25 | $604.7M | $911.3M | ||
| Q4 24 | $629.8M | $907.7M | ||
| Q3 24 | $589.1M | $982.8M | ||
| Q2 24 | $596.5M | $1.0B |
净利润ICUIST
| Q1 26 | — | $87.1M | ||
| Q4 25 | $-15.7M | $63.2M | ||
| Q3 25 | $-3.4M | $-162.5M | ||
| Q2 25 | $35.3M | $60.7M | ||
| Q1 25 | $-15.5M | $69.9M | ||
| Q4 24 | $-23.8M | $5.8M | ||
| Q3 24 | $-33.0M | $-25.0M | ||
| Q2 24 | $-21.4M | $71.7M |
毛利率ICUIST
| Q1 26 | — | 30.6% | ||
| Q4 25 | 37.5% | 29.0% | ||
| Q3 25 | 37.4% | 27.8% | ||
| Q2 25 | 37.9% | 30.3% | ||
| Q1 25 | 34.7% | 29.9% | ||
| Q4 24 | 36.1% | 27.1% | ||
| Q3 24 | 34.8% | 28.6% | ||
| Q2 24 | 34.8% | 30.0% |
营业利润率ICUIST
| Q1 26 | — | 15.1% | ||
| Q4 25 | 1.0% | 10.9% | ||
| Q3 25 | 2.6% | -13.2% | ||
| Q2 25 | 1.9% | 14.6% | ||
| Q1 25 | 2.1% | 13.4% | ||
| Q4 24 | 6.0% | 8.1% | ||
| Q3 24 | 1.4% | -20.3% | ||
| Q2 24 | 1.3% | 12.5% |
净利率ICUIST
| Q1 26 | — | 9.3% | ||
| Q4 25 | -2.9% | 6.9% | ||
| Q3 25 | -0.6% | -17.4% | ||
| Q2 25 | 6.4% | 6.4% | ||
| Q1 25 | -2.6% | 7.7% | ||
| Q4 24 | -3.8% | 0.6% | ||
| Q3 24 | -5.6% | -2.5% | ||
| Q2 24 | -3.6% | 6.9% |
每股收益（稀释后）ICUIST
| Q1 26 | — | $0.59 | ||
| Q4 25 | $-0.63 | $0.45 | ||
| Q3 25 | $-0.14 | $-1.12 | ||
| Q2 25 | $1.43 | $0.41 | ||
| Q1 25 | $-0.63 | $0.47 | ||
| Q4 24 | $-0.97 | $0.05 | ||
| Q3 24 | $-1.35 | $-0.17 | ||
| Q2 24 | $-0.88 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $635.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $2.9B |
| 总资产 | $4.1B | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIST
| Q1 26 | — | $635.1M | ||
| Q4 25 | — | $573.0M | ||
| Q3 25 | — | $791.3M | ||
| Q2 25 | — | $661.8M | ||
| Q1 25 | — | $588.1M | ||
| Q4 24 | $308.6M | $593.7M | ||
| Q3 24 | $312.5M | $506.2M | ||
| Q2 24 | $302.6M | $1.0B |
总债务ICUIST
| Q1 26 | — | — | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ICUIST
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.1B | $2.8B | ||
| Q3 25 | $2.1B | $2.7B | ||
| Q2 25 | $2.1B | $2.9B | ||
| Q1 25 | $2.0B | $2.8B | ||
| Q4 24 | $2.0B | $2.9B | ||
| Q3 24 | $2.0B | $3.0B | ||
| Q2 24 | $2.0B | $3.0B |
总资产ICUIST
| Q1 26 | — | $6.8B | ||
| Q4 25 | $4.1B | $6.8B | ||
| Q3 25 | $4.1B | $7.1B | ||
| Q2 25 | $4.1B | $7.3B | ||
| Q1 25 | $4.2B | $7.2B | ||
| Q4 24 | $4.2B | $7.1B | ||
| Q3 24 | $4.3B | $7.3B | ||
| Q2 24 | $4.3B | $8.2B |
负债/权益比ICUIST
| Q1 26 | — | — | ||
| Q4 25 | — | 1.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.11× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $122.5M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $104.6M |
| 自由现金流率自由现金流/营收 | 6.6% | 11.2% |
| 资本支出强度资本支出/营收 | 4.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.41× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $508.3M |
8季度趋势，按日历期对齐
经营现金流ICUIST
| Q1 26 | — | $122.5M | ||
| Q4 25 | $60.6M | $201.5M | ||
| Q3 25 | $56.7M | $159.9M | ||
| Q2 25 | $11.2M | $140.9M | ||
| Q1 25 | $51.3M | $119.2M | ||
| Q4 24 | $40.2M | $170.7M | ||
| Q3 24 | $36.1M | $130.9M | ||
| Q2 24 | $82.0M | $143.5M |
自由现金流ICUIST
| Q1 26 | — | $104.6M | ||
| Q4 25 | $36.0M | $151.9M | ||
| Q3 25 | $27.6M | $136.2M | ||
| Q2 25 | $-8.5M | $115.5M | ||
| Q1 25 | $36.7M | $86.6M | ||
| Q4 24 | $16.1M | $138.9M | ||
| Q3 24 | $16.2M | $91.3M | ||
| Q2 24 | $62.5M | $98.4M |
自由现金流率ICUIST
| Q1 26 | — | 11.2% | ||
| Q4 25 | 6.6% | 16.6% | ||
| Q3 25 | 5.1% | 14.6% | ||
| Q2 25 | -1.5% | 12.2% | ||
| Q1 25 | 6.1% | 9.5% | ||
| Q4 24 | 2.6% | 15.3% | ||
| Q3 24 | 2.7% | 9.3% | ||
| Q2 24 | 10.5% | 9.5% |
资本支出强度ICUIST
| Q1 26 | — | — | ||
| Q4 25 | 4.6% | 5.4% | ||
| Q3 25 | 5.4% | 2.5% | ||
| Q2 25 | 3.6% | 2.7% | ||
| Q1 25 | 2.4% | 3.6% | ||
| Q4 24 | 3.8% | 3.5% | ||
| Q3 24 | 3.4% | 4.0% | ||
| Q2 24 | 3.3% | 4.4% |
现金转化率ICUIST
| Q1 26 | — | 1.41× | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | 2.32× | ||
| Q1 25 | — | 1.70× | ||
| Q4 24 | — | 29.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
ST
暂无分部数据
